text
"['\n2. 연결재무제표\n가. 연결재무상태표\n분 기 연 결 재 무 상 태 표\n\xa0제 73 기\xa0\xa0 3분기 : 2021년 09월 30일 현재\n제 72 기\xa0 \xa0 \xa0 \xa0 \xa0\xa0 : 2020년 12월 31일 현재\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주\xa0 석\n제 73(당) 3분기\n제 72(전)기\n자\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 산\n\u3000\nI. 현금및현금성자산\n5,6,7\n1,302,516,607,442\n1,051,931,381,296\nII. 예치금\n5,6,7\n1,109,841,763,842\n506,330,448,952\nIII. 당기손익인식유가증권\n5,6,8\n15,248,052,661,099\n8,550,368,155,960\nIV. 매도가능유가증권\n5,6,8\n74,997,194,837,178\n72,051,184,884,412\nV. 관계기업 및 공동기업투자\n10\n363,074,307,808\n257,085,746,882\nVI. 대출채권\n5,6,11\n31,103,145,895,793\n29,596,267,060,058\nVII. 유형자산\n13,14\n1,948,707,606,641\n1,901,701,787,340\nVIII. 투자부동산\n13,14\n2,431,581,633,454\n2,550,620,431,573\nIX. 무형자산\n14\n1,159,989,016,679\n1,133,974,058,283\nX. 사용권자산\n14,15\n154,246,959,988\n80,949,702,614\nXI. 파생상품자산\n5,6,12\n180,730,630,055\n1,050,529,380,184\nXII.순확정급여자산\n23\n1,028,532,502\n4,713,552,970\nXIII. 당기법인세자산\n11,252,510,065\n145,444,942,808\nXIV. 이연법인세자산\n79,718,827,982\n9,177,969,786\nXV. 기타금융자산\n5,6,16\n2,470,650,232,373\n1,536,070,379,766\nXVI. 기타자산\n17\n3,085,351,348,629\n3,026,292,975,678\nXVII. 특별계정자산\n22\n25,974,042,791,640\n25,322,141,175,648\n자\xa0 \xa0 \xa0 산\xa0 \xa0 \xa0 총\xa0 \xa0 \xa0 계\n161,621,126,163,170\n148,774,784,034,210\n부\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 채\nI. 보험계약부채\n18\n107,116,031,811,088\n103,899,220,664,489\nII. 계약자지분조정\n19\n466,945,667,596\n1,208,301,512,727\nIII. 당기손익인식금융부채\n20\n1,450,624,467,627\n-\nIV. 차입부채 및 사채\n21\n7,191,255,410,487\n552,556,975,856\nV. 당기법인세부채\n87,095,436,734\n4,492,704,985\nIV. 이연법인세부채\n583,654,848,773\n1,016,189,709,190\nVII. 파생상품부채\n5,6,12\n1,185,172,719,509\n184,680,143,172\nVIII. 순확정급여부채\n23\n297,171,060,698\n167,036,074,041\nIX.충당부채\n24\n76,032,347,055\n76,210,570,797\nX.기타금융부채\n5,6,15,25\n3,896,003,084,914\n1,910,770,920,248\nXI.기타부채\n26\n240,628,731,995\n203,645,021,676\nXII.특별계정부채\n22\n25,701,068,149,421\n25,607,556,771,196\n부\xa0 \xa0 \xa0 채\xa0 \xa0 \xa0 총\xa0 \xa0 \xa0 계\n148,291,683,735,897\n134,830,661,068,377\n자\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 본\n지배기업의 소유주에게 귀속되는 자본\nI. 자본금\n27\n4,342,650,000,000\n4,342,650,000,000\nII. 기타불입자본\n27\n(453,039,249,785)\n(454,116,554,271)\nIII. 신종자본증권\n28\n2,056,343,999,076\n2,056,343,999,076\nIV. 기타자본구성요소\n29\n537,418,489,790\n2,680,981,572,966\nV. 이익잉여금\n30\n4,765,240,894,662\n4,040,569,740,638\n비지배지분\n2,080,828,293,530\n1,277,694,207,424\n자\xa0 \xa0 \xa0\xa0 본\xa0 \xa0 \xa0\xa0 총\xa0 \xa0 \xa0\xa0 계\n\u3000\n13,329,442,427,273\n13,944,122,965,833\n부\xa0 채\xa0 및\xa0 자\xa0 본\xa0 총\xa0 계\n\u3000\n161,621,126,163,170\n148,774,784,034,210\n나. 연결손익계산서\n\xa0분 기 연 결 포 괄 손 익 계 산 서\n제 73 기 3분기 : 2021년 1월 1일부터 2021년 09월 30일까지\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주 석\n제 73(당) 3분기\n제 72(전) 3분기\n3 개 월\n\xa0누\xa0\xa0 적\n3 개 월\n누\xa0\xa0 적\nI. 영업수익\n7,516,853,855,608\n20,422,694,037,405\n5,650,789,046,203\n19,331,079,455,497\n\xa0 1. 보험료수익\n32\n4,406,716,882,606\n12,285,513,847,503\n4,088,595,948,102\n12,190,870,345,906\n\xa0 2. 재보험수익\n33\n323,609,087,940\n973,035,340,094\n221,546,840,757\n936,143,973,286\n\xa0 3. 이자수익\n31,41\n771,760,107,821\n2,214,879,718,718\n819,787,301,649\n2,311,641,792,852\n\xa0 4. 구상이익\n-\n-\n(188,441,880)\n292,652,399\n\xa0 5. 당기손익인식유가증권 평가 및 처분이익\n31\n101,192,170,398\n326,837,059,342\n64,578,417,609\n135,467,648,202\n\xa0 6. 매도가능유가증권 평가 및 처분이익\n31\n226,982,495,319\n664,734,670,868\n198,187,543,827\n847,531,528,850\n\xa0 7. 외환거래이익\n31\n1,018,091,840,794\n1,998,822,062,210\n(359,567,507,580)\n1,012,424,944,699\n\xa0 8. 파생상품평가 및 거래이익\n12,31\n196,836,544,408\n389,883,013,264\n127,654,036,994\n423,873,033,967\n\xa0 9. 기타수익\n34\n197,280,111,863\n706,508,747,992\n224,525,457,130\n601,990,955,578\n\xa0 10. 특별계정수입수수료\n223,484,705,041\n723,721,893,821\n229,859,778,076\n736,968,302,485\n\xa0 11. 특별계정수익\n22\n50,899,909,418\n138,757,683,593\n35,809,671,519\n133,874,277,273\nII. 영업비용\n7,266,594,667,667\n19,494,956,717,334\n5,443,882,521,411\n18,901,412,482,191\n\xa0 1. 보험계약부채전입액\n18\n1,498,183,275,688\n3,140,428,341,954\n1,162,538,766,411\n3,448,342,816,625\n\xa0 2. 지급보험금\n35,42\n3,128,863,278,989\n9,558,108,982,411\n2,984,901,988,160\n9,214,417,896,582\n\xa0 3. 재보험비용\n33\n375,222,111,231\n1,111,680,412,373\n255,569,191,655\n1,002,983,892,095\n\xa0 4. 사업비\n36,42\n369,549,714,125\n1,455,404,328,097\n489,057,065,456\n1,504,203,433,515\n\xa0 5. 신계약비상각비\n17\n300,894,301,465\n921,391,906,423\n308,388,812,613\n929,444,622,593\n\xa0 6. 재산관리비\n37,42\n29,557,436,594\n104,705,462,958\n23,400,146,896\n95,000,153,622\n\xa0 7. 손해조사비\n38\n31,705,007,260\n90,753,443,820\n31,223,768,162\n87,666,034,396\n\xa0 8. 구상손실\n128,629,878\n1,375,500,468\n-\n-\n\xa0 9. 당기손익인식유가증권 평가 및 처분손실\n31\n69,962,183,710\n117,779,977,970\n(29,518,441,999)\n82,816,294,873\n\xa0 10. 매도가능유가증권 평가 및 처분손실\n31\n45,526,249,525\n74,243,804,700\n122,730,351,325\n320,773,579,130\n\xa0 11. 대출채권및수취채권 평가 및 처분손실\n31\n9,789,575,056\n21,669,956,945\n9,068,442,753\n75,013,284,527\n\xa0 12. 외환거래손실\n31\n38,201,550,334\n86,416,597,929\n55,182,922,274\n244,707,220,307\n\xa0 13. 파생상품평가 및 거래손실\n12,31\n1,113,253,099,091\n2,211,544,249,384\n(196,508,903,942)\n1,325,151,388,536\n\xa0 14. 기타비용\n39\n198,789,932,728\n438,064,130,919\n180,218,528,299\n395,984,696,107\n\xa0 15. 특별계정지급수수료\n6,068,412,575\n22,631,937,390\n11,820,211,829\n41,032,892,010\n\xa0 16. 특별계정비용\n22\n50,899,909,418\n138,757,683,593\n35,809,671,519\n133,874,277,273\nIII. 영업이익\n250,259,187,941\n927,737,320,071\n206,906,524,792\n429,666,973,306\nIV. 영업외수익\n40\n329,448,831,034\n355,560,189,074\n11,806,994,785\n24,944,036,399\nV. 영업외비용\n40\n5,532,359,796\n19,735,996,242\n12,844,512,153\n30,584,238,441\nVI. 법인세비용차감전순이익\n574,175,659,179\n1,263,561,512,903\n205,869,007,424\n424,026,771,264\nVII. 법인세비용\n41\n195,243,428,817\n382,976,673,365\n56,988,823,788\n112,420,492,224\nVIII. 분기순이익\n378,932,230,362\n880,584,839,538\n148,880,183,636\n311,606,279,040\nIX. 법인세비용차감후 기타포괄손익\n(414,258,261,250)\n(2,285,360,241,752)\n152,297,635,174\n1,051,765,026,555\n\xa0 1. 당기손익으로 재분류되지 않는 포괄손익\n(627,615,753)\n13,454,120,826\n460,865,316\n2,386,745,757\n\xa0\xa0 1) 유형자산재평가이익\n(627,615,753)\n3,924,188,061\n460,865,316\n2,480,995,310\n\xa0\xa0 2) 순확정급여부채의 재측정요소\n-\n9,529,932,765\n-\n(94,249,553)\n\xa0 2. 후속적으로 당기손익으로 재분류될 수 \xa0 \xa0 \xa0 있는\xa0포괄손익\n(413,630,645,497)\n(2,298,814,362,578)\n151,836,769,858\n1,049,378,280,798\n\xa0\xa0 1) 매도가능금융자산평가손익\n(399,779,628,702)\n(2,167,266,407,162)\n181,311,402,006\n1,057,176,840,708\n\xa0\xa0 2) 관계기업의 기타포괄손익지분\n1,463,886,401\n4,605,612,664\n178,329,135\n2,829,434,495\n\xa0\xa0 3) 위험회피목적파생상품평가손익\n(25,643,666,609)\n(102,166,751,146)\n(18,998,257,077)\n(41,522,825,851)\n\xa0\xa0 4) 특별계정기타포괄손익\n(25,232,598,689)\n(85,330,829,167)\n7,848,815,260\n33,222,652,615\n\xa0\xa0 5) 해외사업장환산외환차이\n35,561,362,102\n51,344,012,233\n(18,503,519,466)\n(2,327,821,169)\nX. 분기총포괄손익\n(35,326,030,888)\n(1,404,775,402,214)\n301,177,818,810\n1,363,371,305,595\nXI. 분기순손익의 귀속\n378,932,230,362\n880,584,839,538\n148,880,183,636\n311,606,279,040\n\xa0 1. 지배기업의 소유주\n342,888,311,974\n814,323,148,884\n125,444,240,537\n283,944,924,047\n\xa0 2. 비지배지분\n36,043,918,388\n66,261,690,654\n23,435,943,099\n27,661,354,993\nXII. 분기총포괄손익의 귀속\n(35,326,030,889)\n(1,404,775,402,214)\n301,177,818,810\n1,363,371,305,595\n\xa0 1. 지배기업의 소유주\n(84,804,542,016)\n(1,324,560,591,937)\n264,165,156,784\n1,261,520,410,097\n\xa0 2. 비지배지분\n49,478,511,127\n(80,214,810,277)\n37,012,662,026\n101,850,895,498\nXIII. 주당이익\n\xa0 1. 기본 및 희석주당이익\xa0\n422\n986\n135\n279\n다. 연결자본변동표\n분 기 연 결 자 본 변 동 표\n제 73 기 3분기 : 2021년 1월 1일부터 2021년 09월 30일까지\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 목\n자\xa0 본\xa0 금\n기타불입자본\n신종자본증권\n기타자본구성요소\n이익잉여금\n지배기업의소유주 귀속\n비지배지분\n총\xa0 \xa0 계\n2020.1.1 (전기초)\n4,342,650,000,000\n(457,886,936,004)\n2,056,297,477,526\n2,820,597,421,914\n3,924,201,158,687\n12,685,859,122,123\n1,307,416,095,811\n13,993,275,217,934\nI. 분기총포괄손익\n\xa0 1. 분기순이익\n-\n-\n-\n-\n283,944,924,047\n283,944,924,047\n27,661,354,993\n311,606,279,040\n\xa0 2. 재평가잉여금의대체\n-\n-\n-\n(5,622,158)\n5,622,158\n-\n-\n-\n\xa0 3. 유형자산재평가손익\n-\n-\n-\n2,480,995,310\n-\n2,480,995,310\n-\n2,480,995,310\xa0\n\xa0 4. 순확정급여부채의 재측정요소\n-\n-\n-\n(94,249,553)\n-\n(94,249,553)\n-\n(94,249,553)\n\xa0 5. 매도가능금융자산평가손익\n-\n-\n-\n984,830,235,220\n-\n984,830,235,220\n72,346,605,488\n1,057,176,840,708\xa0\n\xa0 6. 관계기업의 기타포괄손익지분\n-\n-\n-\n3,383,750,375\n-\n3,383,750,375\n(554,315,880)\n2,829,434,495\xa0\n\xa0 7. 위험회피목적파생상품평가손익\n-\n-\n-\n(43,957,116,098)\n-\n(43,957,116,098)\n2,434,290,247\n(41,522,825,851)\n\xa0 8. 특별계정기타포괄손익\n-\n-\n-\n33,228,665,156\n-\n33,228,665,156\n(6,012,541)\n33,222,652,615\n\xa0 9. 해외사업환산손익\n-\n-\n-\n(2,296,794,360)\n-\n(2,296,794,360)\n(31,026,809)\n(2,327,821,169)\nII. 자본에 직접 인식된 주주와의 거래\n\xa0 1. 연차배당\n-\n-\n-\n-\n(22,541,707,500)\n(22,541,707,500)\n-\n(22,541,707,500)\n\xa0 2. 신종자본증권 발행\n-\n-\n46,521,550\n-\n-\n46,521,550\n-\n46,521,550\n\xa0 3. 신종자본증권 배당\n-\n-\n-\n-\n(73,960,362,936)\n(73,960,362,936)\n(8,353,333,338)\n(82,313,696,274)\n\xa0 4. 주식기준보상\n-\n560,205,560\n-\n-\n-\n560,205,560\n-\n560,205,560\n\xa0\xa05. 자기주식처분손실\n-\n1,137\n-\n-\n-\n1,137\n1,077\n2,214\n2020.9.30 (전분기말)\n4,342,650,000,000\n(457,326,729,307)\n2,056,343,999,076\n3,798,167,285,806\n4,111,649,634,456\n13,851,484,190,031\n1,400,913,659,048\n15,252,397,849,079\n2021.1.1 (당기초)\n4,342,650,000,000\n(454,116,554,271)\n2,056,343,999,076\n2,680,981,572,966\n4,040,569,740,638\n12,666,428,758,409\n1,277,694,207,424\n13,944,122,965,833\nI. 분기총포괄손익\n\xa01. 분기순이익\n-\n-\n-\n-\n814,323,148,884\n814,323,148,884\n66,261,690,654\n880,584,839,538\n\xa02. 재평가잉여금의대체\n-\n-\n-\n(4,682,004,631)\n4,682,004,631\n-\n-\n-\n\xa03. 유형자산재평가이익\n-\n-\n-\n3,924,188,061\n-\n3,924,188,061\n-\n3,924,188,061\n\xa04. 확정급여제도의 재측정요소\n-\n-\n-\n9,529,932,765\n-\n9,529,932,765\n-\n9,529,932,765\n\xa05. 매도가능금융자산평가손익\n-\n-\n-\n(2,024,929,535,984)\n-\n(2,024,929,535,984)\n(142,336,871,178)\n(2,167,266,407,162)\n\xa06. 관계기업의 기타포괄손익지분\n-\n-\n-\n5,156,175,139\n-\n5,156,175,139\n(550,562,475)\n4,605,612,664\n\xa07. 위험회피목적파생상품평가손익\n-\n-\n-\n(96,862,829,587)\n-\n(96,862,829,587)\n(5,303,921,559)\n(102,166,751,146)\n\xa08. 특별계정기타포괄손익\n-\n-\n-\n(85,310,749,057)\n-\n(85,310,749,057)\n(20,080,110)\n(85,330,829,167)\n\xa09. 해외사업환산손익\n-\n-\n-\n49,609,077,842\n-\n49,609,077,842\n1,734,934,391\n51,344,012,233\nII. 자본에 직접 인식된 주주와의 거래\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\xa01. 연차배당\n-\n-\n-\n-\n(22,541,707,500)\n(22,541,707,500)\n-\n(22,541,707,500)\n\xa02. 신종자본증권 배당\n-\n-\n-\n-\n(71,792,291,991)\n(71,792,291,991)\n(9,240,000,000)\n(81,032,291,991)\n\xa03. 주식기준보상\n-\n2,275,966,350\n-\n-\n-\n2,275,966,350\n718,534,220\n2,994,500,570\nⅢ. 비지배지분의 증감\n-\n(1,198,661,864)\n-\n2,662,276\n-\n(1,195,999,588)\n891,870,362,163\n890,674,362,575\n2021.9.30 (당분기말)\n4,342,650,000,000\n(453,039,249,785)\n2,056,343,999,076\n537,418,489,790\n4,765,240,894,662\n11,248,614,133,743\n2,080,828,293,530\n13,329,442,427,273\n라. 연결현금흐름표\n분 기 연 결 현 금 흐 름 표\n제 73 기 3분기 : 2021년 1월 1일부터 2021년 09월 30일까지\n제 72 기 3분기 : 2020년 1월 1일부터 2020년 09월 30일까지\n한화생명보험주식회사와 그 종속기업\n(단위 : 원)\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n주 석\n제 73(당) 3분기\n제 72(전) 3분기\nⅠ. 영업활동으로 인한 현금흐름\n3,923,471,716,237\n1,499,495,718,433\n\xa0 \xa0 1.\xa0분기순이익\n880,584,839,538\n311,606,279,040\n\xa0 \xa0 2. 조정\n44\n1,127,902,277,468\n1,986,778,267,525\n\xa0 \xa0 3. 영업활동으로 인한 자산ㆍ부채의 변동\n44\n(712,982,049,601)\n(3,411,740,509,585)\n\xa0 \xa0 4. 이자의 수취\n2,203,750,099,815\n2,237,930,010,191\n\xa0 \xa0 5. 이자의 지급\n(35,166,920,839)\n(19,478,787,565)\n\xa0 \xa0 6. 배당금의 수취\n445,500,289,613\n369,997,756,889\n\xa0 \xa0 7.\xa0법인세환급액(부담액)\n13,883,180,242\n24,402,701,938\nⅡ. 투자활동으로 인한 현금흐름\n(4,084,396,232,971)\n(1,296,785,485,871)\n\xa0 \xa0 1. 매도가능금융자산의 처분\n6,989,927,970,203\n11,998,361,012,277\n\xa0 \xa0 2. 투자부동산 및 유형자산의 처분\n102,766,371,889\n4,048,641,246\n\xa0 \xa0 3. 무형자산의 처분\n5,617,152,950\n8,324,574,659\n\xa0 \xa0 4. 관계기업투자의 처분\n129,598,028,311\n6,057,000,000\n\xa0 \xa0 5. 관계기업투자의 배당\n6,509,548,418\n7,047,894,439\n\xa0 \xa0 6. 금융리스채권의 감소\n46,827,210\n-\n\xa0 \xa0 7. 예치보증금의 감소\n13,038,202,352\n21,835,458,244\n\xa0 \xa0 8. 기타부채의 증가\n905,000,000\n-\n\xa0 \xa0 9. 매도가능금융자산의 취득\n(11,049,042,185,349)\n(12,403,253,635,313)\n\xa0 \xa0 10. 위험회피목적 파생상품의 정산\n10,609,040,783\n(767,745,923,173)\n\xa0 \xa0 11. 투자부동산 및 유형자산의 취득\n(51,887,480,604)\n(48,441,500,857)\n\xa0 \xa0 12. 관계기업투자의 취득\n(36,939,894,629)\n(26,616,442,784)\n\xa0 \xa0 13. 무형자산의 취득\n(66,841,783,284)\n(68,643,854,220)\n\xa0 \xa0 14. 예치보증금의 증가\n(6,533,330,795)\n(7,951,739,863)\n\xa0 \xa0 15. 투자활동 관련 선급금 유출\n(13,465,569,390)\n-\n\xa0 \xa0 16. 연결범위변동으로 인한 현금흐름\n(118,704,131,036)\n(19,806,970,526)\nⅢ. 재무활동으로 인한 현금흐름\n404,867,654,111\n(66,373,221,550)\n\xa0 \xa0 1. 비지배지분의 증가\n39,240,486,873\n-\n\xa0 \xa0 2. 비지배지분의 감소\n(9,753,401,950)\n(8,353,333,338)\n\xa0 \xa0 3. 임대보증금 증가\n8,288,702,591\n11,174,386,681\n\xa0 \xa0 4. 임대보증금 감소\n(13,624,992,404)\n(8,099,029,988)\n\xa0 \xa0 5. 신종자본증권 발행\n-\n46,521,550\n\xa0 \xa0 6. 신종자본증권 배당\n(52,666,400,000)\n(64,568,050,000)\n\xa0 \xa0 7. 배당금의 지급\n(22,541,707,500)\n(22,541,707,500)\n\xa0 \xa0 8. 자기주식의 처분\n-\n2,215\n\xa0 \xa0 9. 차입금의 감소\n(147,891,234,388)\n(53,354,143,000)\n\xa0 \xa0 10. 차입금의 증가\n497,813,698,679\n52,759,307,367\n\xa0 \xa0 11. 기타금융부채의 변동\n50,946,266,757\n66,360,548,624\n\xa0 \xa0 12. 리스부채의 감소\n(44,759,715,839)\n(39,797,724,161)\n\xa0 \xa0 13. 환매조건부채권매도의 순증감\n99,815,951,292\n-\nⅣ. 현금및현금성자산의 순증가(감소)(Ⅰ+Ⅱ+Ⅲ)\n243,943,137,377\n136,337,011,012\nⅤ. 기초 현금및현금성자산\n1,051,931,381,296\n950,704,341,946\nⅥ. 외화표시 현금및현금성자산 환율변동효과\n6,642,088,769\n(3,150,714,984)\nⅦ. 분기말 현금및현금성자산\n1,302,516,607,442\n1,083,890,637,974\n']"
